Obesity: Biophytis Charts Its Course Toward a Booming Market Biophytis is seizing a major opportunity in the expanding obesity market by addressing an unmet medical need: preserving muscle mass and function in patients losing weight while treated with GLP-1 receptor agonists. GLP-1 therapies such as semaglutide and tirzepatide have revolutionized obesity management by enabling significant…
Biophytis Highlights Innovative Approach to Obesity Treatment During Key ECO 2025 Presentation Biophytis announced its active participation at the 32nd European Congress on Obesity (ECO 2025), held from May 11 to 14 in Malaga, Spain. During this premier international event, which brings together leading experts, clinicians, researchers, and industry stakeholders to discuss the latest advances…
Biophytis targets mobility restoration in patients with obesity Biophytis strentghens its position as one of the leading players in preserving muscle function in patients with obesity treated with GLP-1 therapies. While these treatments are revolutionizing obesity care by delivering significant weight loss, they also induce a concerning loss of muscle mass, which can compromise patients’…
Biophytis announces new non-clinical data further supporting its mission to pioneer the restoration of mobility in patients with obesity 96% of patients with obesity report experiencing muscle strength impairment, affecting their mobility. New preclinical study results: The combination of BIO101 and GLP-1 induced muscle strength and mobility restoration in animal model. Biophytis announces new preclinical…
Biophytis Announces New Cash Contribution and Debt Conversion up to €8.6 million to Finance the Obesity Program Cash contribution of €2.5 million from existing and new investors to finance the clinical development of BIO101 in obesity Conversion into equity of debt for up to €6.1 million strengthening the balance sheet Biophytis announces the completion of…
Biophytis showcased the OBA program in obesity at the 17th SCWD international congress Biophytis took part in the 17th international SCWD (Society on Sarcopenia, Cachexia & Wasting disorders) congress, a flagship event bringing together experts from around the world to share innovations on sarcopenia, cachexia and muscle wasting including weight loss induced muscle disorders. At…
Biophytis its participation in the 17th edition of the SCWD Congress (Society on Sarcopenia, Cachexia & Wasting Disorders), taking place from December 6 to 8, 2024, in Washington, D.C. As part of the congress, Biophytis will host an Obesity Investor Call on the topic: “GLP-1 RA weight loss therapy-induced muscle loss: A medical need to…
Biophytis is deploying its partnership strategy in obesity Biophytis today the implementation of a dedicated strategy for partner search in obesity. Biophytis is continually working on the search for partners thanks to a sound strategy and action plan, with the Company being fully committed to drive groundbreaking scientific and technological advances that have the potential…
Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) Promising preclinical results obtained in obesity support the OBA Phase 2 clinical study expected to start mid-2024 Biophytis announces that it is launching a new clinical development program named OBA, with BIO101 (20- hydroxyecdysone) as a potential treatment for obesity in combination with…
